Laurus Synthesishttp://www.laurussynthesis.com has inked a deal to collaborate with Epygenix Therapeutics for the development and manufacture of their lead candidate EPX-100.

Laurus Synthesis will provide chemistry development services and manufacturing in support of an upcoming clinical trial for EPX-100 in adolescents suffering from Dravet syndrome. Like most genetic forms of epilepsy, Dravet syndrome represents an orphan indication with an unmet medical need.

“Epygenix is proud to be supported by Laurus in developing a new therapy for this devastating disease,” said Hahn-Jun Lee, founder and chief executive officer, Epygenix Therapeutics. “Our collaboration efforts with Laurus will be able to help many children who are suffering from this intractable genetic epilepsy.”

Charles Montgomery, vice president chemistry, Laurus Synthesis, said, “This collaboration validates LSI’s ability to assist companies with challenging chemistry development. Our goal is to outperform expectations so that our clients can reach their business milestones quickly and effectively.”

Laurus Synthesis delivers its drug chemistry solutions from a laboratory facility in Woburn, MA, and works synergistically with colleagues at Laurus Labs and Laurus Synthesis India to provide optimum speed and cost efficiency for clients.